OraSure Technologies Q2 Earnings Call Highlights

OraSure Technologies NASDAQ: OSUR reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth in sample-management products supported results.

MarketBeat • Aug 6, 2026

OraSure Technologies, Inc. (OSUR) Q2 2026 Earnings Call Transcript

OraSure Technologies, Inc. (OSUR) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

OraSure Announces Second Quarter 2026 Financial Results

BETHLEHEM, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2026.

GlobeNewsWire • Aug 5, 2026

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5 p.m. Eastern Time on that day.

GlobeNewsWire • Jul 22, 2026

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients. The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients.

GlobeNewsWire • Jul 21, 2026

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche's tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems.

GlobeNewsWire • Jun 11, 2026

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

OraSure Announces First Quarter 2026 Financial Results

BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.

GlobeNewsWire • May 6, 2026

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026.

GlobeNewsWire • Apr 22, 2026

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D.

GlobeNewsWire • Apr 17, 2026